Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Endocrinology
•
Peripheral Vascular Disease
Do you prioritize prescribing semaglutide in patients with type 2 diabetes and peripheral arterial disease, given trial data demonstrating improved maximum walking distance with its use?
Bonaca MP, et al.,
PMID 40169145
Related Questions
Would the diagnostic yield for ABIs or peripheral arterial duplex doppler in a patient with metal rods in both legs be similar or acceptable in comparison to those tests in a patient without metal rods?
Would you consider a short duration of dual antiplatelet therapy following plain old balloon angioplasty (POBA) to a femoropopliteal bypass graft
Which type of patients with asymptomatic peripheral arterial disease with an ABI score of less than 0.9, is it reasonable to offer antiplatelet and statin therapy to?
Is azilsartan superior to other angiotension receptor blockers in regard to cardiorenal outcome data?
What patient factors do you consider when selecting between a small interfering RNA, like inclisiran, and PCSK9 inhibitors in patients with recent acute coronary syndrome?
What are your preferred lipid-lowering agents and target LDL reduction goal following initiation of therapy for patients with familial hyperlipidemia without underlying CAD?
How often do you recommend performing an advanced lipid panel for monitoring of lipid lowering therapy?
How do you evaluate the etiology of worsening limb ischemia between progression of known PAD or cardioembolic disease?
Is it a good practice to prescribe clonidine to take as needed for occasional severe blood pressure elevations?
What is the clinical significance of a paradoxical decrease in HDL cholesterol after starting statin therapy?
